Breaking News Instant updates and real-time market news.

FPRX

Five Prime

$44.77

-1.1 (-2.40%)

16:17
03/01/17
03/01
16:17
03/01/17
16:17

Five Prime initiated with a Buy at Nomura

Nomura initiated Five Prime with a Buy and a $94 price target.

  • 01

    Apr

FPRX Five Prime
$44.77

-1.1 (-2.40%)

05/11/16
05/11/16
NO CHANGE

Leerink major pharma & biotech analyst holds analyst/industry conference call
Biotech Analyst Schmidt and Major Pharmaceuticals Analyst Fernandez, along with University of Chicago Departments of Pathology & Medicine, Professor Dr. Thomas F. Gajewski, discuss the tumor micro-environment on an Analyst/Industry conference call to be held on May 11 at 2 pm.
08/09/16
WELS
08/09/16
NO CHANGE
WELS
Five Prime weakness overdone, says Wells Fargo
After a trial of the OPDIVO cancer treatment of Five Prime's (FPRX) partner, Bristol Myers Squibb (BMY), showed disappointing results, Wells Fargo thinks that the nearly 9% decline in Five Prime's stock was overdone. The firm thinks that it's "premature" to determine that Merck's (MRK) Keytruda has overtaken OPDIVO. The firm believes that Five Prime's OPDIVO can redeem itself in upcoming studies, and it thinks that Five Prime's stock can advance if the actor-1 receptor is proven to be a worthwhile target ,whether or not OPDIVO is shown to be effective. The firm keeps an Outperform rating on Five Prime.
10/25/16
SBSH
10/25/16
INITIATION
Target $65
SBSH
Buy
Five Prime initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Five Prime Therapeutics with a Buy rating and $65 price target. The company has "multiple shots" on goal in various cancers, Karnauskas tells investors in a research note. She believes investors will assign higher value to the Cabiralizumab program once combo data with Opdivo is seen in 2017. The analyst sees fair value for Five Prime shares in the $65-$80 range.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.